Semaglutide in Obese Women With PCOS: Real-World Weight Loss and Metabolic Improvements
In a real-world clinical setting, obese women with PCOS lost an average of 11.4% of their body weight on semaglutide, with significant improvements in blood pressure, blood sugar, cholesterol, and menstrual regularity.
Quick Facts
What This Study Found
Across 58 obese women with PCOS treated with semaglutide in routine clinical practice, mean weight loss was 12.6 ± 9.6 kg, representing 11.4% of total body weight (p < 0.0001). Seventy-nine percent of participants lost more than 5% of their body weight — the threshold considered clinically meaningful for PCOS.
Mean BMI dropped from 40.7 to 36.2 kg/m² (p < 0.0001). Systolic blood pressure fell by 6.3 mmHg (p = 0.012). HbA1c decreased from 35.3 to 33 mmol/mol (p = 0.0014). Total cholesterol dropped from 4.8 to 4.45 mmol/L (p = 0.03). Among those with irregular periods, 50% reported subjective improvement, while 33% with acne and 29% with hirsutism also noted improvements.
Key Numbers
n=58; 12.6 kg mean weight loss (11.4%); BMI 40.7→36.2; SBP -6.3mmHg; HbA1c 35.3→33 mmol/mol; 79% lost >5% body weight; 50% improved menstrual cycles
How They Did This
This was a retrospective review of medical records from 58 women with both PCOS and obesity who were attending reproductive endocrinology clinics and had been prescribed semaglutide for at least 6 months. The researchers collected data on weight, BMI, blood pressure, HbA1c, cholesterol, and self-reported changes in menstrual regularity, acne, and excess hair growth before and after treatment.
Why This Research Matters
Clinical guidelines suggest GLP-1 receptor agonists could help women with PCOS, but they've noted a lack of evidence. This study fills part of that gap with real-world data showing semaglutide delivers substantial weight loss and metabolic improvements in this specific population — well beyond the 5% weight loss threshold known to improve PCOS outcomes.
The Bigger Picture
PCOS affects up to 13% of women of reproductive age, and obesity worsens nearly every aspect of the syndrome — from metabolic risk to fertility to androgen symptoms. While semaglutide is well-studied for obesity and diabetes, evidence specifically in PCOS has been limited. This study adds to a growing body of real-world data suggesting that GLP-1 agonists may be particularly well-suited for this population, addressing both the metabolic and reproductive dimensions of the syndrome.
What This Study Doesn't Tell Us
This was a retrospective study with no control group, so the improvements can't be definitively attributed to semaglutide alone. Menstrual, acne, and hirsutism improvements were based on subjective patient reports rather than objective measurements. The study was conducted at a single center in Ireland. The sample size of 58 is relatively small, and there was considerable variation in individual weight loss responses (standard deviation of 9.6 kg).
Questions This Raises
- ?Would a randomized controlled trial confirm these metabolic and reproductive benefits of semaglutide specifically in PCOS?
- ?Does the weight loss from semaglutide in PCOS translate to improved fertility outcomes?
- ?How do the benefits compare in women with PCOS who have lower BMIs versus the severely obese population studied here?
Trust & Context
- Key Stat:
- 11.4% body weight lost Obese women with PCOS lost an average of 12.6 kg on semaglutide — well above the 5% threshold that guidelines say meaningfully improves PCOS outcomes.
- Evidence Grade:
- Rated moderate: real-world clinical data from a defined patient population with statistically significant results across multiple outcomes. However, the retrospective design, lack of control group, small sample size, and subjective symptom reporting limit the strength of causal conclusions.
- Study Age:
- Published in 2026 in the Irish Journal of Medical Science. This is very current research addressing an active gap in the evidence base for GLP-1 agonists in PCOS.
- Original Title:
- The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.
- Published In:
- Irish journal of medical science, 195(1), 131-136 (2026)
- Authors:
- Alawami, Fatimah, Novaes, Olivia, Gibney, James, Phelan, Niamh, Behan, Lucy Ann, Owens, Lisa
- Database ID:
- RPEP-14733
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Can semaglutide help with PCOS symptoms beyond weight loss?
In this study, yes — beyond the 11.4% average weight loss, half of women with irregular periods reported improvement, and about a third saw better acne and excess hair growth. Blood pressure, blood sugar, and cholesterol also improved significantly.
How much weight did PCOS patients lose on semaglutide compared to general obesity studies?
The 11.4% body weight loss is comparable to results seen in major semaglutide trials for general obesity. Importantly, 79% of these PCOS patients exceeded the 5% loss threshold that guidelines consider clinically meaningful for improving PCOS outcomes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-14733APA
Alawami, Fatimah; Novaes, Olivia; Gibney, James; Phelan, Niamh; Behan, Lucy Ann; Owens, Lisa. (2026). The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.. Irish journal of medical science, 195(1), 131-136. https://doi.org/10.1007/s11845-025-04194-x
MLA
Alawami, Fatimah, et al. "The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.." Irish journal of medical science, 2026. https://doi.org/10.1007/s11845-025-04194-x
RethinkPeptides
RethinkPeptides Research Database. "The metabolic benefits associated with semaglutide use in ob..." RPEP-14733. Retrieved from https://rethinkpeptides.com/research/alawami-2026-the-metabolic-benefits-associated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.